$SLNO News
Last published 2mo ago
- 2mo agoSLNOKuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Soleno Therapeutics, Inc. (NASDAQ:...
- 4mo agoPVLASVRASLNOSBBP+2Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of DirectorsGlobeNewswireBrings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease
- 6mo agoSLNOThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Soleno Therapeutics, Inc. Lawsuit - SLNOGlobeNewswireNEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ:SLNO). Shareholders who purchased shares of SLNO during the class period
- 7mo agoSLNOFolia Health Launches "BRAVE-PWS" Study to Better Understand the Real-World Experience of Prader-Willi Syndrome CaregiversGlobeNewswireBOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Folia Health announces the launch of Burden and Real-world Assessment of Caregiver Voice and Experiences in Prader-Willi syndrome (BRAVE-PWS), a fully remote observational
- 7mo agoNBIXSLNONeurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease PortfolioPR NewswireNeurocrine Biosciences, Inc. (Nasdaq: NBIX) and Soleno Therapeutics, Inc. (Nasdaq: SLNO) today announced that Neurocrine has entered into a...
- 7mo agoSLNOREMINDER: Soleno Therapeutics, Inc. Investors With Significant Losses Must Act By May 5, 2026 – Contact Kirby McInerneyGlobeNewswireNEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO) investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a
- 8mo agoSLNOSoleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial OfficerGlobeNewswireREDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 8mo agoSLNOSoleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XRGlobeNewswireREDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported
- 9mo agoSLNOSoleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ETGlobeNewswireREDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 9mo agoSLNOSoleno Therapeutics to Participate in Upcoming ConferencesGlobeNewswireREDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 10mo agoSLNOSoleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 ResultsGlobeNewswireREDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 10mo agoSLNOSLNO Investigation: Investors Encouraged to Contact Kirby McInerney LLPGlobeNewswireNEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO) investors concerning
- 10mo agoSLNOSoleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and MetabolismGlobeNewswireREDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a
- 10mo agoSLNOSoleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (SLNO)Business WireThe law firm of Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO). The investigation concerns whether the Company and/or members of its
- 11mo agoSLNOSoleno Therapeutics Announces the Passing of Board Member William G. HarrisGlobeNewswireREDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to
- 11mo agoSLNOSoleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase AgreementGlobeNewswireREDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today
- 1y agoSLNOSoleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XRGlobeNewswireREDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported
- 1y agoSLNOSoleno Therapeutics to Participate in Upcoming November ConferencesGlobeNewswireREDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ETGlobeNewswireREDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics, Inc. (SLNO) Under Investigation After Scorpion Capital Report Raises Drug Safety Concerns; Investors Urged to Contact Award-Winning Firm, Gibbs MuraBusiness WireShares of Soleno Therapeutics, Inc. ("Soleno") fell over 12% on September 10, 2025, after the company disclosed a patient death involving its treatment for Prader-Willi Syndrome, VYKAT XR. Previously, on Friday, August
- 1y agoSLNOSoleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoSLNOSoleno Therapeutics, Inc. (SLNO) Presents At Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoSLNOSoleno Therapeutics to Participate in Upcoming September ConferencesGlobeNewswireREDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics, Inc. (SLNO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoSLNOSoleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial ResultsGlobeNewswireREDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an
- 1y agoSLNOSoleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ETGlobeNewswireREDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Announces Pricing of $200 Million Public Offering of Common StockGlobeNewswireREDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today
- 1y agoSLNOSoleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025GlobeNewswireREDWOOD CITY, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome ConferenceGlobeNewswireREDWOOD CITY, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted
- 1y agoSLNOSoleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome ConferenceGlobeNewswireREDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi SyndromeGlobeNewswireREDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics to Participate in Upcoming June ConferencesGlobeNewswireREDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi SyndromeGlobeNewswireREDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data
- 1y agoSLNOSoleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025GlobeNewswireREDWOOD CITY, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025GlobeNewswireREDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025GlobeNewswireREDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial ResultsGlobeNewswireREDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an
- 1y agoSLNOSoleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ETGlobeNewswireREDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Announces VYKAT(TM) XR LaunchGlobeNewswireREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced
- 1y agoSLNOSoleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi SyndromeGlobeNewswireFirst approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE
- 1y agoSLNOApproval of Vykat Xr, Nda #216665 (Type 2 - New Active Ingredient)FDA Approved DrugsApproval Date: 03/26/2025; Drug Name: Vykat Xr, Nda #216665; Active Ingredients: DIAZOXIDE CHOLINE; Company: Soleno Therapeutics Inc; Submission Status: Approval; Submission Classification: Type 2 - New Active Ingredient; Application Number: 216665
- 1y agoSLNOSoleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial ResultsGlobeNewswireREDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a
- 1y agoSLNOSoleno Therapeutics to Participate in Upcoming February Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
- 1y agoSLNOSoleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLCGlobeNewswireREDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
- 1y agoSLNOSoleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
- 1y agoSLNOSoleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi SyndromeGlobeNewswireREDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
- 1y agoSLNOSoleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024GlobeNewswireREDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
- 2y agoSLNOSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswireREDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,